- Hepion Pharmaceuticals Inc HEPA stock is moving higher during premarket ahead of additional data from its non-alcoholic steatohepatitis (NASH) trial.
- Today, Hepion will share additional data from the Phase 2a AMBITION trial, evaluating CRV431, a potent inhibitor of cyclophilins involved in many disease processes.
- As previously disclosed, the trial achieved all primary endpoints.
- Related Content: Hepion Pharma's NASH Candidate Aces Mid-Stage Study.
- Price Action: HEPA shares are up 16.9% at $1.94 during the premarket session on the last check Monday.
Loading...
Loading...
HEPAHepion Pharmaceuticals Inc
$0.099212.7%
Edge Rankings
Momentum
Not Available
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
